Our target partners are the 5 pharmaceutical companies that manufacture Alzheimer’s medications.

With our unique nano biotechnology, we will re-formulate existing Alzheimer’s drugs, providing the nano carrier for their drug delivery.

Years 1 - 2: Complete proof of principle, utilizing capital from seed investors.

Years 3 - 6: Research & Development, utilizing capital from Big Pharma companies.

Years 7 - 10: Clinical Trials, receive milestone payments from Big Pharma companies.